Quarterly report pursuant to Section 13 or 15(d)

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Mar. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Abstract]

SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES

		Initial Valuations (on new derivative instruments entered into during the nine months ended March 31, 2024)				March 31, 2024
Volatility			327.58 – 333.45	%			319.08	%
Expected Remaining Term (in years)			0.50				0.01 - 0.03
Risk Free Interest Rate			5.43 - 5.55	%			5.49	%
Expected dividend yield			None				None

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS

		Balance at March 31, 2024				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs
						(Level 1)				(Level 2)				(Level 3)
Embedded conversion option liabilities		$	128,432			$	—			$	—			$	128,432
Total		$	128,432			$	—			$	—			$	128,432

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2024

(Unaudited)

		Balance at June 30, 2023				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs
						(Level 1)				(Level 2)				(Level 3)
Embedded conversion option liabilities		$	423,209			$	—			$	—			$	423,209
Total		$	423,209			$	—			$	—			$	423,209

SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE

		Fair Value of Liability for Derivative Instruments
Balance at June 30, 2023		$	423,209
Beginning balance		$	423,209
Initial fair value of embedded conversion option derivative liability recorded as debt discount			125,000
Initial fair value of embedded conversion option derivative liability recorded as derivative expense			123,379
Reduction of derivative liability upon debt conversion			(170,785	)
Change in fair value included in statements of operations			(372,371	)
Balance at March 31, 2024		$	128,432
Ending balance		$	128,432